Prolonged therapy with non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis: renal status
- Authors: Rebrov A.P1, Aparkina A.V1, Khondkaryan E.V1, Gaidukova I.Z2
-
Affiliations:
- FSBI HE "Saratov State Medical University. V.l. Razumovsky" of the Ministry of Health of the Russian Federation
- FSBI HE ''North-Western State Medical University n.a. I.I. Mechnikov'' of the Ministry of Health of the Russian Federation
- Issue: No 1 (2019)
- Pages: 56-60
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/273228
- DOI: https://doi.org/10.18565/nephrology.2019.1.56-60
- ID: 273228
Cite item
Open Access
Access granted
Abstract
Objective. Analysis of the renal status in patients with axial spondyloarthritis (SpA), taking non-steroidal antiinflammatory drugs (NSAIDs) continuously for 24 months. Material and methods. 12 and 24 months from the start of continuous administration of NSAIDs, the glomerular filtration rate (GFR), urine α1-MicROGLOBULiN and albumin levels equivalent to 1 g of urinary creatinine were determined in 36 patients with SpA without an initial renal failure. results. 24 months after start of study, the average GFR was 107.0 [93.0; 125.0] ml/min/1.73 m2, urine ai-Microglobulin was 24.78 [19.87; 34.73] mg/g (P>0.05 for differences with baseline value) against the background of continuous use of NSAIDs. a marked increase in the urine albumin level TO 44.24 [28.46; 85.96] mg/g (P=0.035 compared with baseline level and with urine albumin levels after 12 months of treatment). After 24 months of follow-up, the deviation in three indicators (GFR, microglobulin, urine albumin level) was revealed in 2 (5.6%) patients with SpA. An increase in the urine albumin or α1-Microglobulin level or a decrease in gfr of less than 90 ml/min/ 1.73 m2 was detected in 10 (27.8%) patients. 7 (19.4%) patients showed abnormalities in two markers of renal damage. Overall, kidney damage was recorded in 18 (50%) patients with SpA. In all patients, gfr corresponded to chronic kidney disease stage 1-2. Conclusion. Against the background of continuous use of NSAIDs for 24 months, 18 (50%) patients with SpA showed some changes in the renal status. Kidney damage from all established cases was more common in patients taking diclofenac sodium.
Full Text
About the authors
A. P Rebrov
FSBI HE "Saratov State Medical University. V.l. Razumovsky" of the Ministry of Health of the Russian Federation
Email: andreyrebrov@yandex.ru
Doctor of Medical Sciences, Professor, Head of the Department of Hospital Therapy, Faculty of Medicine Saratov, Russia
A. V Aparkina
FSBI HE "Saratov State Medical University. V.l. Razumovsky" of the Ministry of Health of the Russian Federation
Email: alena437539@yandex.ru
PhD in Medical Sciences, Teaching Assistant at the Department of Hospital Therapy, Faculty of Medicine Saratov, Russia
E. V Khondkaryan
FSBI HE "Saratov State Medical University. V.l. Razumovsky" of the Ministry of Health of the Russian Federation
Email: ersilasolnce@mail.ru
PhD in Medical Sciences, Teaching Assistant at the Department of Hospital Therapy, Faculty of Medicine Saratov, Russia
I. Z Gaidukova
FSBI HE ''North-Western State Medical University n.a. I.I. Mechnikov'' of the Ministry of Health of the Russian Federation
Email: ubp1976@list.ru
Doctor of Medical Sciences, Professor at the Department of Therapy, Rheumatology, Examination of Temporary Disability Saint-Petersburg, Russia
References
- van der Heijde D., Ramiro S., Landewe R., et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017; 76: 978-991.
- Гайдукова И.З., Ребров А.П., Коротаева Т.В. и др. Ремиссия при аксиальных спондилоартритах - определение и инструменты оценки (рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России»). Научнопрактическая ревматология. 2018; 56(1): 10-14.
- Lories R.J., Luyten F.P., de Vlam К. Progress in spondyloarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthr. Research. Ther. 2009; 11(2): 221. doi: 10.1186/ar2642.
- Poddubnyy D., van der Heijde D. Therapeutic controversies in spondyloar-thritis: nonsteroidal anti-inflammatory drugs. Rheum. Dis. Clin. North Am. 2012; 38(3): 601-611.
- Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009; 150(9): 604-612.
- Simon L.S. Nonsteroidal anti-inflammatory drugs and their risk: a story still in development. Arthr. Res+. Ther. 2013; 15(Suppl. 3): 1.
- Snively C.S., Gutierrez C. Chronic kidney disease: prevention and treatment of common complications. Am. Fam. Physician. 2004; 70(10): 1921-1928.
- Hsu C.C., et al. Use of nonsteroidal anti-inflammatory drugs and risk of chronic kidney disease in subjects with hypertension: nationwide longitudinal cohort study. Hypertension. 2015.pii: HYPERTENSIONAHA.114.05105. [Epub ahead of print].
- Ingrasciotta Y., Sultana J., Giorgianni F, Patrizio Caputi A., Arcoraci V., Ugo Tari D., Linguiti C., Perrotta M., Nucita A., Fabio Pellegrini, Fontana A., Cavagna L., Santoro D., Trifird G. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS One. 2014; 9(2): e89072. doi: 10.1371/journal.pone.0089072.
- Wen-Chan Tsai, Tsan-Teng Ou, Jeng-Hsien Yen, Cheng-Chin Wu, Yi-Ching Tung. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015; 10(5): e0126347. doi: 10.1371/journal.pone.0126347.
Supplementary files
